University of Pennsylvania joins Actinium Pharmaceuticals' Multicenter Actimab-A Trial

    University of Pennsylvania joins Actinium Pharmaceuticals' Multicenter
                               Actimab-A Trial

Actinium Pharmaceuticals further expands its Phase I/II clinical trial in
acute myeloid leukemia patients

PR Newswire

NEW YORK, Jan. 17, 2013

NEW YORK, Jan. 17, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (API),
a public biopharmaceutical company (OTC BB: CTVN) that develops innovative
targeted payload immunotherapeutics, announced that the University of
Pennsylvania Health System in Philadelphia, PA has joined the Company's
ongoing Phase I/II trial in newly diagnosed elderly patients with acute
myeloid leukemia (AML). The trial is designed to establish the safety and
efficacy of API's drug Actimab-A in AML patients over the age of 60.
Actimab-A treatment consists of the isotope Actinium 225 attached to the
anti-CD33 monoclonal antibody lintuzumab (HuM195).

"We are pleased to welcome UPenn as an additional site in our multicenter
trial, another clear validation point as we continue to make solid progress,"
said Jack Talley, CEO of Actinium Pharmaceuticals. "Five of the leading
leukemia treatment centers that have been setting the pace in new approaches
to AML have now expressed their readiness to be our partners in bringing the
benefits of alpha particle immunotherapy technology to patients in need of new
approaches. We look forward to building on this momentum throughout the year."

The University of Pennsylvania Health System is the fifth center to sign a
clinical trial agreement with Actinium Pharmaceuticals, following Memorial
Sloan Kettering Cancer Center (MSKCC) in New York, NY, Fred Hutchinson Cancer
Research Center (FHCRC) in Seattle, WA, MD Anderson Cancer Center in Houston,
TX and Johns Hopkins in Baltimore, MD.

The phase I/II multi-center Actimab study builds on the previous phase I/II
Bismab-A study with a less potent bismuth-213 (Bi-213) isotope and an earlier
Actimab-A phase 1 study (where only a single dose of Actimab was
administered). The Phase II portion of the earlier Bismab-A study
demonstrated the efficacy of API's alpha particle platform by producing a
number of complete responses in difficult-to-treat relapsed, secondary and
poor cytogenetics AML patients with no standard of care options available. The
goal of the current study is to confirm the efficacy and safety of Actimab-A
using the same antibody targeting mechanism with the actinium isotope,
produced by an improved method of manufacture, and to study the effect of
multiple doses of treatment. The population for this study will be patients
with newly diagnosed AML who are over the age of 60, an age in which many
chemotherapy regimens are not well tolerated. In other published studies in
AML, newly diagnosed patients had better responses than relapsed patients.

About Actimab-A
Actimab-A is a drug candidate construct made using Actinium Pharmaceuticals'
proprietary patented technology for arming monoclonal antibodies with alpha
emitters actinium 225 and bismuth 213. Antibodies are used as high precision
delivery systems that bring powerful alpha emitters into or immediately next
to targeted cancer cells. Actimab-A consists of the Lintuzumab monoclonal
antibody and actinium 225.

Actinium-225 decays by giving off high-energy alpha particles, which kill
cancer cells. When actinium decays, it produces a series of daughter atoms,
each of which gives off its own alpha particle, increasing the chances that
the cancer cell will be destroyed. The technology was first developed by Dr.
David Scheinberg at Memorial Sloan Kettering Cancer Center.

Lintuzumab is a monoclonal antibody that targets CD33, found on myeloid
leukemia cells. It is the humanized version of M195, the antibody initially
developed by Dr. David Scheinberg of Memorial Sloan Kettering Cancer Center.

About Actinium Pharmaceuticals
Actinium Pharmaceuticals, a public New York, New York based
biopharmaceutical company that develops innovative alpha particle
immunotherapeutics based on its proprietary platform for the therapeutic
utilization of alpha particle emitting actinium-225 and bismuth-213
radiopharmaceuticals in association with monoclonal antibodies.

For more information:

Visit our web site  or contact:

Jack Talley, CEO
Actinium Pharmaceuticals Inc.
Tel: (646) 459-4201

Jeff Ramson
ProActive Capital Group, LLC
Tel: (646) 863-6341

Dennis S. Dobson Jr., 203-258-0159

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as that term is
defined in the Private Securities Litigation Reform Act of 1995. These
statements are based on management's current expectations and involve risks
and uncertainties, which may cause results to differ materially from those set
forth in the statements. The forward-looking statements may include statements
regarding product development, product potential, or financial performance.
No forward-looking statement can be guaranteed and actual results may differ
materially from those projected. Actinium Pharmaceuticals undertakes no
obligation to publicly update any forward-looking statement, whether as a
result of new information, future events, or otherwise.

SOURCE Actinium Pharmaceuticals, Inc.

Press spacebar to pause and continue. Press esc to stop.